OssDsign AB (publ) has received approval for listing of the company’s shares on Nasdaq First North
Nasdaq has approved OssDsign AB (publ) (”OssDsign” or the ”Company”) for listing on Nasdaq First North. First day of trading in the Company’s shares is Friday, May 24, 2019.
OssDsign has recently completed a new share issue prior to listing on Nasdaq First North. The share issue was oversubscribed and raised SEK 151.3M before issue costs. Provided that the over-allotment option of up to an additional 825,000 shares is fully exercised, the Company will receive a total of SEK 174M before issue costs. The subscription price in the share issue was SEK 27.50 per share. Following the share issue, OssDsign will have around 2,000 shareholders.
Nasdaq’s review of OssDsign has now been completed and the Company’s application for admission to trading on Nasdaq First North is approved. Nasdaq’s approval is conditional upon that the Company fulfills customary terms. The shares will be traded under the ticker OSSD and with ISIN code SE0012570448.
For further information, refer to the prospectus that has been prepared in connection with the share issue and application for listing. The prospectus is available on OssDsign’s website, www.ossdsign.com.
Erik Penser Bank is the financial advisor in connection with the Offer. SV Ventures has acted as Co-Advisor to the Company in strategic matters related to the Offer and Setterwalls Advokatbyrå is the legal advisor in connection with the Offer.
The Company’s Certified Adviser is Erik Penser Bank AB. Contact information: Erik Penser Bank AB, Box 7405, 103 91 Stockholm, Sweden, phone: +46 (0)8-463 80 00, email: email@example.com.
For further information, please contact:
Anders Lundqvist, CEO, OssDsign AB
Phone: +46 73 206 98 08, email: firstname.lastname@example.org
OssDsign is a Swedish medical technology company that develops and manufactures regenerative implants for improved healing of bone defects. Providing neuro and plastic surgeons with innovative implants, OssDsign improves the outcome for patients with severe cranial and facial defects worldwide. By combining clinical knowledge with proprietary technology, OssDsign manufactures and sells a growing range of patient-specific solutions for treating cranial defects and facial reconstruction. OssDsign's technology is the result of collaboration between clinical researchers at Karolinska University Hospital in Stockholm and material scientists at the Ångström Laboratory at Uppsala University.